Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse

Avinash S Bidra, Jesse S Pelletier, Jonna B Westover, Samantha Frank, Seth M Brown, Belachew Tessema, Avinash S Bidra, Jesse S Pelletier, Jonna B Westover, Samantha Frank, Seth M Brown, Belachew Tessema

Abstract

Purpose: To investigate the optimal contact time and concentration for viricidal activity of oral preparation of povidone-iodine (PVP-I) against SARS-CoV-2 ('corona virus') to mitigate the risk and transmission of the virus in the dental practice.

Materials and methods: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) USA-WA1/2020 strain, virus stock was tested against oral antiseptic solutions consisting of aqueous povidone-iodine (PVP-I) as the sole active ingredient. The PVP-I was tested at diluted concentrations of 0.5%, 1%, and 1.5%. Test media without any virus was added to 2 tubes of the compounds to serve as toxicity and neutralization controls. Ethanol (70%) was tested in parallel as a positive control, and water only as a negative control. The test solutions and virus were incubated at room temperature (22 ± 2 °C) for time periods of 15 and 30 seconds. The solution was then neutralized by a 1/10 dilution in minimum essential medium (MEM) 2% fetal bovine serum (FBS), 50 µg/mL gentamicin. Surviving virus from each sample was quantified by standard end-point dilution assay and the log reduction value (LRV) of each compound compared to the negative (water) control was calculated.

Results: PVP-I oral antiseptics at all tested concentrations of 0.5%, 1%, and 1.5%, completely inactivated SARS-CoV-2 within 15 seconds of contact. The 70% ethanol control group was unable to completely inactivate SARS-CoV-2 after 15 seconds of contact, but was able to inactivate the virus at 30 seconds of contact.

Conclusions: PVP-I oral antiseptic preparations rapidly inactivated SARS-CoV-2 virus in vitro. The viricidal activity was present at the lowest concentration of 0.5 % PVP-I and at the lowest contact time of 15 seconds. This important finding can justify the use of preprocedural oral rinsing with PVP-I (for patients and health care providers) may be useful as an adjunct to personal protective equipment, for dental and surgical specialties during the COVID-19 pandemic.

Keywords: SARS-CoV-2; corona virus; dental safety; oral rinse; povidone-iodine.

© 2020 The Authors. Journal of Prosthodontics published by Wiley Periodicals LLC on behalf of American College of Prosthodontists.

References

    1. Lu H, Stratton CW, Tang YW: Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol 2020;92:401‐402
    1. Zou L, Ruan F, Huang M, et al: SARS‐CoV‐2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382:1177‐1179
    1. Sungnak, W , Huang N, Bécavin C, et al: SARS‐CoV‐2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020;26:681‐687
    1. Harrel SK, Molinari J: Aerosols and splatter in dentistry: a brief review of the literature and infection control implications. J Am Dent Assoc 2004;135:429‐437
    1. Micik RE, Miller RL, Mazzarella MA, et al: Studies on dental aerobiology, I: bacterial aerosols generated during dental procedures. J Dent Res 1969;48:49‐56
    1. Miller RL, Micik RE, Abel C, et al: Studies of dental aerobiology, II: microbial splatter discharged from the oral cavity of dental patients. J Dent Res 1971;50:621‐625
    1. Micik RE, Miller RL, Leong AC: Studies on dental aerobiology, III: efficacy of surgical masks in protecting dental personnel from airborne bacterial particles. J Dent Res 1971;50:626‐630
    1. ADA Interim Guidance for Minimizing Risk of COVID‐19 Transmission . . Accessed May 28, 2020
    1. The Centers for Disease Control and Prevention (CDC) . Interim Infection Prevention and Control Guidance for Dental Settings During the COVID‐19 Response. Accessed May 28, 2020
    1. Eggers M, Koburger‐Janssen T, Eickmann M, et al: In vitro bactericidal and virucidal efficacy of povidone‐iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther 2018;7:249‐259
    1. Kariwa H, Fujii N, Takashima I: Inactivation of SARS coronavirus by means of povidoneiodine, physical conditions and chemical reagents. Dermatology 2006;212(Suppl): 119‐123
    1. Reed, LJ , Muench, H : A simple method of estimating fifty percent endpoints. Am J Epidemiol 1938;27:493‐497
    1. Tessema B, Frank S, Bidra AS. SARS‐CoV‐2 viral inactivation using low dose povidone‐iodine oral rinse‐immediate application for the prosthodontic practice. Letter to the Editor, J Prosthodont, May 2020. 10.1111/jopr.13207
    1. Tsuda S, Soutome S, Hayashida S, et al: Topical povidone iodine inhibits bacterial growth in the oral cavity of patients on mechanical ventilation: a randomized controlled study. BMC Oral Health 2020;20:62
    1. Perrella FA, Rovai EDS, De Marco AC, et al. Clinical and microbiological evaluation of povidone‐iodine 10% as an adjunct to nonsurgical periodontal therapy in chronic periodontitis: a randomized clinical trial. J Int Acad Periodontol 2016;18:109‐119
    1. Stein JM, Hammächer C, Michael SS: Combination of ultrasonic decontamination, soft tissue curettage, and submucosal air polishing with povidone‐iodine application for non‐surgical therapy of peri‐implantitis: 12 Month clinical outcomes. J Periodontol 2018;89:139‐147
    1. Managutti A, Managutti SA, Patel J: Evaluation of Post‐surgical Bacteremia with Use of Povidone‐Iodine and Chlorhexidine During Mandibular Third Molar Surgery. J Maxillofac Oral Surg 2017;16:485‐490
    1. Frank S, Capriotti J, Brown SM, et al: Povidone‐iodine use in sinonasal and oral cavities: A review of safety in the COVID‐19 era. Ear Nose Throat J May 2020. Accepted and In press.
    1. Reimer K, Wichelhaus TA, Schafer V: Antimicrobial effectiveness of povidone‐iodine and consequences for new application areas. Dermatology 2002;204 Suppl 1:114‐20
    1. Madan PD, Sequeira PS, Shenoy K, et al: The effect of three mouthwashes on radiation‐induced oral mucositis in patients with head and neck malignancies: a randomized control trial. J Cancer Res Ther 2008;4:3‐8
    1. Panchmatia R, Payandeh J, Al‐Salman R, et al: The efficacy of diluted topical povidone‐iodine rinses in the management of recalcitrant chronic rhinosinusitis: a prospective cohort study. Eur Arch Otorhinolaryngol 2019;276:3373‐3381
    1. Ader AW, Paul TL, Reinhardt W, et al: Effect of mouth rinsing with two polyvinylpyrrolidone‐iodine mixtures on iodine absorption and thyroid function. J Clin Endocrinol Metab 1988;66:632‐5
    1. Kovesi G: The use of betadine antiseptic in the treatment of oral surgical, paradontological and oral mucosal diseases. Fogorvosi szemle 1999;92:243‐250
    1. Domingo MA, Farrales MS, Loya RM, et al: The effect of 1% povidone iodine as a pre‐procedural mouth rinse in 20 patients with varying degrees of oral hygiene. J Philipp Dent Assoc 1996;48:31‐8
    1. Foley TP Jr: The relationship between autoimmune thyroid disease and iodine intake: a review. Endokrynol Pol 1992;43 Suppl 1:53‐69
    1. Furudate S, Nishimaki T, Muto T: 125I uptake competing with iodine absorption by the thyroid gland following povidone‐iodine skin application. Exp. Anim 1997;46:197‐202
    1. Gray PEA, Katelaris CH, Lipson D: Recurrent anaphylaxis caused by topical povidone iodine (Betadine). J Paediatr Child Health 2013;49:506‐7
    1. Kampf G, Todt D, Pfaender S, et al: Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104:246‐251

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit